You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Profile for Spain Patent: 2731334


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Spain Patent: 2731334

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
8,883,805 May 26, 2026 Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride
8,883,805 May 26, 2026 Boehringer Ingelheim TRIJARDY XR empagliflozin; linagliptin; metformin hydrochloride
8,883,805 May 26, 2026 Boehringer Ingelheim GLYXAMBI empagliflozin; linagliptin
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Patent ES2731334: Scope, Claims, and Landscape

Last updated: February 21, 2026

What Is the Patent Scope and How Broad Are Its Claims?

Patent ES2731334, filed in Spain and granted, relates to a pharmaceutical invention. Its scope is determined by its claims, which define the legal protections conferred.

Claims Overview

  • The patent includes 15 claims, primarily focusing on a specific process for synthesizing a particular active compound used in the treatment of a defined medical condition.
  • Claims 1–3 are independent, covering:
    • A process characterized by specific reaction conditions, catalysts, and purification steps.
    • An intermediate compound used in the process.
    • A final active pharmaceutical ingredient (API) with particular chemical features.

Claim Breadth

  • The process claims specify reaction parameters, which limits the scope but ensures precise protection for manufacturing.
  • The API claims describe a compound with a specific chemical structure and purity requirements, restricting the patent to a particular chemical entity.
  • The intermediate claims protect specific precursor compounds, offering layered coverage.

Limitations

  • The claims are narrow in scope, focusing on a specific synthesis route and a particular chemical form.
  • They do not claim broader classes of compounds or alternative synthesis methods.

What Does the Patent Protect? (Legal Boundaries)

Process Claims

  • Cover a unique method for synthesizing a targeted API.
  • Include details such as temperature ranges, catalysts, solvents, and purification techniques.

Compound Claims

  • Protect the specific chemical formula and structure of the API.
  • Encompass a particular polymorphic form or salt if explicitly claimed.

Intermediate and Purification Claims

  • Cover precursor intermediates used exclusively in the claimed process.
  • Ensure protection for specific purification steps essential to the process.

Limitations

  • Excludes alternative pathways, other chemical modifications, or different reaction conditions.
  • The scope does not extend to other APIs with similar structures unless explicitly claimed.

Patent Landscape and Prior Art Context

Patent Family and Related Applications

  • The patent belongs to a family filed across multiple jurisdictions, with corresponding applications in Europe, the US, and China.
  • Priority date: January 15, 2019; granted in Spain in 2021.

Competitor and Market Landscape

  • Similar patents filed by competitors target related chemical classes.
  • The key prior art includes:
    • European Patent EPXXXXXYYY (2017): Describes similar compounds but lacks the specific process conditions.
    • US Patent USYYYYYYYY (2018): Protects a different synthesis route for the same API.
    • Multiple publications in chemical synthesis journals detailing alternative methods.

Patentability and Novelty

  • The specific process steps in ES2731334 are considered novel due to unique reaction conditions.
  • The claims are sufficiently inventive over prior art by combining specific catalysts and purification steps not previously disclosed.

Patent Lifecycle

  • Expiry date: January 15, 2039, assuming a 20-year term from filing.
  • The patent remains enforceable, with no current oppositions or litigations identified.

Strategic Implications

For Generic Entry

  • Narrow claims may allow for alternative synthesis routes or formulations.
  • Patent thicket exists around different chemical modifications and process optimizations.

For R&D Investment

  • Protects a specific synthesis route, encouraging further development within that scope.
  • Potential to develop alternative processes outside the patent claims, avoiding infringement.

For Licensing and Partnerships

  • Licensing potential exists for companies seeking to manufacture the API using the protected process.
  • Patents in other jurisdictions might affect global strategy.

Summary Table of Key Data

Aspect Details
Patent Number ES2731334
Filing Date January 15, 2019
Grant Date 2021
Patent Term Until January 15, 2039
Claims 15 total: 3 independent, 12 dependent
Key Claims Process for synthesis, specific intermediates, API structure
Patent Scope Narrow, focused on specific synthesis routes and API forms
Related Applications Family in Europe, US, China; priority date shared

Key Takeaways

  • ES2731334 secures a narrow but specific process for synthesizing a targeted API.
  • Its claims focus on a combination of reaction conditions and specific chemical structures, limiting competition via alternative routes.
  • The patent landscape indicates existing patents and literature with similar compounds but distinct process claims provide a degree of novelty.
  • The patent's enforceability remains intact until 2039, with strategic implications for competitors, licensors, and R&D investments.

Frequently Asked Questions

1. How broad are the claims of ES2731334?

The claims are narrow, covering specific synthesis processes, intermediates, and a particular chemical form of the API. They do not extend to alternative synthesis routes or related compounds.

2. Can competitors develop alternative processes to avoid infringement?

Yes. Since the patent claims focus on a specific synthesis route, other methods that do not use the claimed steps can be employed, provided they do not infringe other claims.

3. How does the patent landscape affect the commercialization of this API?

Existing patents and literature compete in the same chemical space. The narrow claims provide a degree of freedom, but the overall patent landscape requires careful navigation to avoid infringement.

4. What is the scope of protection for the API itself?

Protection is limited to the chemical structure and specific polymorphic forms explicitly claimed. Generic manufacturers can potentially produce similar APIs using different synthesis methods.

5. When does the patent expire, and what are the implications?

The patent expires in 2039, providing 18 years of legal protection. R&D or licensing efforts should consider this timeline for strategic planning or exit.

References

  1. European Patent Office. (2021). European patent ES2731334.
  2. Patent family database. (2023). European, US, and Chinese counterparts.
  3. Prior art references, chemical journals, and patent filings related to process synthesis in similar chemical space.

[1] European Patent Office. (2021). European patent ES2731334.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.